Medincell: U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

About this update from Medincell Sa

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1772,"height":295,"url":"https://media.zenfs.com/en/business-wire.com/2221018e0a753b57770284803473c743"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/05HJkkh8nvdkS6bcw9oAbw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2221018e0a753b57770284803473c743","width":960,"height":160},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/HA9LFjo_8y5QEKZOnN9YPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2221018e0a753b57770284803473c743","width":1200,"height":200}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Olanzapine long-acting injectable suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation 1","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations1","length":184,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Teva is committed to advancing this innovative treatment option and further building on its differentiated LAI franchise and scientific leadership in complex neurological conditions as it drives forward its Pivot to Growth strategy","length":231,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":574,"olType":false},{"type":"text","content":"PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS, February 20, 2026--(BUSINESS WIRE)--Regulatory News:","length":105,"tagName":"p"},{"type":"text","content":"Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. TEV-'749 is designed to improve real-world treatment adherence and help patients maintain long-term stability, with the goal of addressing a critical treatment gap for people living with schizophrenia.",...

More updates from Medincell Sa